Clinical Trial Update: Safety and Efficacy Study of ATGC-100 for the Treatment of Moderate to Severe Glabellar Lines in Adult Subjects [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ATGC-100 assessing safety and efficacy in treating moderate to severe glabellar lines (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• To Severe Glabellar Lines

Drugs mentioned

• ATGC-100

Snippet

Sponsor: EuBiologics Co.,Ltd | Conditions: Moderate to Severe Glabellar Lines | Phase 1, Phase 2 | Status: COMPLETED